TrialHaematologica2014

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.

Timothy P Hughes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.